Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Bionano Genomics, Inc. BNGO NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
47/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$46.50
+3743%

Bionano Genomics, Inc. (BNGO) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $1.21. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is BNGO = $47 (+3743% upside).

Valuation: BNGO trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25).

Financials: revenue is $29M, +2.6%/yr average growth. Net income is $26M (loss), growing at +17.6%/yr. Net profit margin is -92.6% (negative). Gross margin is 22% (+0.6 pp trend).

Balance sheet: total debt is $7M against $44M equity (Debt-to-Equity (D/E) ratio 0.16, conservative). Current ratio is 1.98 (strong liquidity). Debt-to-assets is 9.4%. Total assets: $74M.

Analyst outlook: 4 / 7 analysts rate BNGO as buy (57%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 63/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 25/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).

$46.50
▲ 3742.98% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Bionano Genomics, Inc., the average price target is $46.50, with a high forecast of $175.00, and a low forecast of $1.00.
Highest Price Target
$175.00
Average Price Target
$46.50
Lowest Price Target
$1.00

BNGO SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 63/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 25/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BNGO

✓
VALUE Pass
100/100
BNGO trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25). Analyst consensus target is $47, implying +3784.3% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
63/100
BNGO: +2.6%/yr revenue is, +17.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet BNGO: Debt-to-Equity (D/E) ratio 0.16 (conservative), Current ratio is 1.98 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
25/100
BNGO: Gross margin is 22% (+0.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 25/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 4 / 7 analysts rate BNGO as buy (57%). Analyst consensus target is $47 (+3784.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
BNGO: Net profit margin is -92.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.06-5.5
Volume209.04K
Avg Volume (30D)353.88K
Market Cap$3.97M
Beta (1Y)1.60
Share Statistics
EPS (TTM)-4.85
Shares Outstanding$5.45M
IPO Date2018-08-21
Employees98
CEORobert Erik Holmlin
Financial Highlights & Ratios
Revenue (TTM)$28.51M
Gross Profit$6.26M
EBITDA$-23.61M
Net Income$-26.4M
Operating Income$-33.34M
Total Cash$13.26M
Total Debt$6.92M
Net Debt$3.93M
Total Assets$73.58M
Price / Earnings (P/E)-0.2
Price / Sales (P/S)0.14
Analyst Forecast
1Y Price Target$5.00
Target High$175.00
Target Low$1.00
Upside+313.2%
Rating ConsensusBuy
Analysts Covering7
Buy 57% Hold 43% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS09075F4046

Price Chart

Track all markets on TradingView
BNGO
Bionano Genomics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Diagnostics & Research
1.06 52WK RANGE 5.50

People Also View

ISRG
ISRG
Intuitive Surgical, Inc.
$467.22
+1.80%
 BDX
BDX
Becton, Dickinson and Company
$155.73
+0.19%
 RMD
RMD
ResMed Inc.
$230.69
+0.19%
 WST
WST
West Pharmaceutical Services, Inc.
$267.93
+3.07%
 NVST
NVST
Envista Holdings Corp
$27.38
+1.75%
 STAA
STAA
STAAR Surgical Company
$24.43
-8.98%
 STXS
STXS
Stereotaxis, Inc.
$2.03
+5.73%
 MBOT
MBOT
Microbot Medical Inc.
$2.43
+3.40%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message